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Background: Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in
hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent
hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a
translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending
neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and
neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance
between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of
p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated.
Methods: Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using
a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were
determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were
assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology.
Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders
Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for
statistical analysis.
Results: Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated
the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before
visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas
SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the
IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of
healthy subjects exposed to IH (0.97± 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to
normoxic controls (1.0±0.5 vs.1.99±0.3, p=0.015), and Bax did not co-localize with mitochondria.
Conclusions: These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro
as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different
signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH.
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Neutrophils are bone marrow derived short-lived cells
which provide a unique model to study survival signal-
ing. Once released into the circulation, neutrophils
undergo constitutive apoptosis. However, their lifespan
is prolonged in coronary syndromes such as unstable an-
gina and acute myocardial infarction and in respiratory
diseases such as chronic obstructive pulmonary disease
(COPD) and neonatal and adult respiratory distress syn-
drome (RDS) [1-4]. Prolonged neutrophil survival is also
evident in patients with obstructive sleep apnea (OSA),
characterized by repeated nightly episodes of intermit-
tent hypoxia (IH) [5]. Of note, increased neutrophil sur-
vival within tissues or in the circulation can promote
persistent inflammation resulting in tissue injury and
dysfunction.
Unlike in other cells, sustained hypoxia (SH) as well as
IH were shown to profoundly inhibit neutrophil apop-
tosis in-vitro [5-9] and in-vivo [5,10]. Specifically in SH
several signaling pathways and a number of family mole-
cules that regulate apoptosis are activated. B-cell
lymphocytic-leukaemia proto-oncogene (Bcl)-2 family
members are one such family, which can be either pro-
apoptotic (Bax and Bak, as well as BH3-only proteins,
Bid, Bim, Bad, Bik, Noxa, PUMA) or anti-apoptotic
(Mcl-1, Bcl-2, Bcl-X and A1) [11-14]. The Bcl-2 family
members are integrated in cell functions at the level of
the mitochondria and participate in the regulation of
stress-induced apoptosis [15-17].
Bcl-2 associated X protein (Bax) is necessary for indu-
cing apoptosis [18] and its translocation and redistribu-
tion to the mitochondria is essential for implementing
the apoptotic program [15,18,19]. Therefore, Bax is con-
sidered a quantitative marker of early apoptotic events
[13,16,20-22]. Anti-apoptotic stimuli inhibit Bax inser-
tion into the mitochondrial membrane, thereby inhibit-
ing its pro-apoptotic activity [13]. On the other hand,
myeloid cell leukemia 1 (Mcl-1) promotes neutrophil
survival by binding and sequestering Bak and Bax, which
are capable of forming pores in the mitochondrial mem-
brane [23]. Mcl-1 is up-regulated in response to various
survival stimuli [23-29] and is required for neutrophil
viability under SH [30,31]. Importantly, decrease in Mcl-
1 levels precedes the appearance of the apoptotic
morphology [32].
MAPKs, in particular p38 [33-35] and ERK [36,37]
regulate the apoptotic program in neutrophils. Specific-
ally, Mcl-1 expression might be regulated by signal
transduction through ERK [28]. ERK is also responsible
for increasing Mcl-1 through protein stabilization by
granulocyte-macrophage colony-stimulating factor (GM-
CSF) [25]. Sustained hypoxia can increase neutrophil
survival by activating p38MAPK signaling, thereby indu-
cing Mcl-1 proteins [30].Previously we have shown that NF-κB, its downstream
gene IL-8, CXCR2 receptor expression, and p38MAPK
signaling pathways are essential for controlling neutro-
phil survival in healthy individuals treated with IH
in-vitro via the extrinsic pathway which is Fas receptors
and TNF-α dependent [9]. To further elucidate the
mechanisms involved in prolonging neurtophil survival
under IH in-vitro as well as in patients with OSA, herein
we investigated the intrinsic stress-induced mitochon-
drial pathway. These effects of IH were investigated dur-
ing the early pro-apoptotic events, which occurred in
neutrophils before the appearance of morphological
changes and caspase’s cascade activation. Thus, we show
that Bax expression was decreased and its translocation
to the mitochondria was inhibited under IH in-vitro.
Concurrently, Mcl-1 expression was up-regulated via ac-
tivation of ERK1/2 and p38MAPK dependent signaling
pathways. Finally, we ascertained the involvement of the
mitochondrial network in prolonging the survival of
neutrophils in patients with OSA. Similar to the IH
in-vitro model, in OSA patients which represent an IH
in-vivo model, Bax did not co-localize with the mito-
chondria and Bax/Mcl-1 ratio was significantly lower
than in healthy controls.
Methods
Neutrophil isolation and treatment
Blood samples were obtained from 10 healthy volunteers
(age=35.8±11.9 yr, BMI=25.3±2.6 Kg/m2) and from 7
OSA patients (age=51.4±15.4 yr, BMI=30.2±5.5 Kg/m2,
apnea-hypopnea index (AHI)=35.7±20 events/hrs). All
control subjects and OSA patients were free from cardio-
vascular disease or diabetes and had normal blood pressure
values (not higher than 140/90 mm Hg). All controls and
most OSA patients did not take medications for at least 2
weeks before the study was conducted. Two OSA patients
used irregularly low-dose acetyl salicylic acid (micropirin-
75). In 7/10 healthy-controls, AHI (2.1±1.8 events/hrs) was
determined by a validated home monitored device (watch-
PAT-100 Itamar Medical, Caesarea, Israel) [38] and 3/10
controls underwent full-night polysomnography (AHI 8.0
±1.7 events/hrs) as all OSA patients (Technion Sleep
Medicine Center, Haifa). OSA diagnosis was based on the
recommendations of the American Academy of Sleep
Medicine Task Force with a cutoff point of AHI≥10 [39].
Lipid profile and high sensitivity C-reactive protein (CRP)
were determined in patients and controls as previously
described [5]. The protocol was approved by the local
Human Rights Committee, and all participants signed an
informed consent form.
Blood samples were withdrawn under fasting condi-
tions and polymononuclear cells (PMNs) were isolated
using a two layer Ficoll-Histopaque density gradient cen-
trifugation (Histopaque 1.077 and 1.119, Sigma-Aldrich,
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96%, and viability was greater than 99%, as determined
by trypan blue exclusion. Purified PMNs were resus-
pended in RPMI-1640 medium, supplemented with 10%
FCS and 1 mM L-glutamine, plated without/with inhibi-
tors and exposed to normoxia, SH or IH using the
BioSpherix-OxyCycler C42 system as we described pre-
viously [5,9].
Light-microscopy assessment of neutrophil apoptosis
Purified neutrophils’ cytospin preparations were fixed,
and stained with May Grunwald-Giemsa. Slides were
read blindly by Axiovert 25 (Zeizz) light microscope. At
least 300 cells/slide were analyzed. Cells showing apop-
totic morphology were identified according to the fol-
lowing criteria: nuclear condensation in the form of a
single nucleus or nuclear fragments not connected by
strands [40,41].
In-vitro IH and SH protocol
Purified PMNs (0.6 ml per well; 3–4 × 106 cells/ml) were
plated into 24 well plates and then were exposed to nor-
moxia, SH or IH in custom-designed incubation cham-
bers which are attached to an external O2-CO2-N2
computer-driven controller using BioSpherix-OxyCycler-
C42 system (Redfield, NY, USA). This system which
enables to create periodic changes in external O2 con-
centrations that control air gas levels in each chamber
individually was described in detail previously [5,9].
Briefly, for IH, the O2 saturation in the medium was
kept at 2% for 6.6 ± 3.6 min durations, out of each 1 hr
cycle. In each experiment 6 IH cycles were run. SH was
employed for a comparable time at 2% actual oxygen in
the medium for the entire period. Control purified
PMNs were maintained in normoxic conditions for the
same durations. Oxygen levels in the medium were
determined by a fiber-optic dissolved oxygen electrode
(BioSpherix, Redfield, NY, USA).
Western blot analysis
PMNs cultured in normoxia, IH or SH, were lysed in
Tris buffered Saline Triton -X (TBST) at pH 7.4 (50 mM
Tris–HCl, 150 mM NaCl, 0.5% Triton X-100, 0.2 mM
sodium vanadate), supplemented with a mixture of
protease inhibitors (Roche Diagnostics GmbH, Roche
Applied Science, Mannheim, Germany), and stored
at −80°C until use. Cell lysates were centrifuged at
16,000 × g for 15 min and protein concentration was
determined by Bradford reagent (Bio-Rad Laboratories
GmbH, Munich, Germany). Cell lysates (50 μg) were run
on 12% SDS-PAGE and transferred onto Hybond nitro-
cellulose membranes (Amersham Biosciences Europe
GmbH, Freiburg, Germany). Membranes were blocked
and incubated with primary rabbit polyclonal antibodiesagainst Thr180/Tyr182-phosphorylated p38MAPK
(Cell Signaling Technology, Inc., Beverly, MA, USA),
Thr202/Tyr204-phosphorylated ERK1/2 (Cell Signaling
Technology, Inc., Beverly, MA, USA), Bax (N20, sc493)
and Mcl-1 (S-19, sc819, Santa Cruz Biotechnology Inc.,
CA, USA), followed by goat anti-rabbit IgG incubation
(Amersham Biosciences Europe GmbH, Freiburg,
Germany). Then membranes were washed six times with
TBST buffer and incubated with horseradish peroxidase-
conjugated secondary antibody (goat anti-rabbit IgG;
Amersham Biosciences Europe GmbH, Freiburg,
Germany) for 1 hr at room temperature. Densitometric
analysis was performed using TotalLab TL100 v.2006c
software (Nonlinear Dynamics Ltd., Newcastle Upon
Tyne, UK), and is expressed in arbitrary units.Confocal laser scanning microscopy
Viable neutrophils were stained with 100 nM Mito-
Tracker Orange CMTMRos (Invitrogen, Molecular
Probes, Eugene, Oregon, USA) for mitochondria [42].
Then fixed, Triton-permeabilized and labeled with anti-
Bax (N20, sc493) or anti-Mcl-1(S-19, sc819) polyclonal
antibodies (Santa Cruz Biotechnology Inc., CA, USA)
followed by CyTM2-conjugated Goat anti-Rabbit IgG
incubation (Jackson ImmunoResearch Laboratories, Inc.,
Baltimore Pike, PA, USA). Nuclei were stained with
TO-PRO-3 (Invitrogen Inc., Carlsbad, CA, USA). Slides
were mounted with fluorescence mounting medium
(Vectashield H-1000, Vector lab Inc., Burlingame, CA,
USA) and were analyzed by confocal laser scanning
fluorescence system (Radiance 2000) with Nikon E600
(Japan) camera. Controls for staining included a primary
nonspecific rabbit IgG, secondary antibodies and five-
fold excess Mcl-1 blocking peptide (sc819 P, Santa Cruz
Biotechnology Inc., CA, USA).Quantitative fluorescence intensity and
co-localization analysis
Relative quantitation of green (Bax) and red (Mitochon-
drial staining) fluorescence of each cell was accom-
plished by acquiring grayscale images and fluorescence
intensities were integrated using ImageJ 1.42q (Wayne
Rasband National Institute of Health, USA).
Co-localization of Bax and mitochondria was quantified
by LSM 510 CarlZeiss MicroImaging GmbH v.4.2 R&D
in collaboration with EmBl, Heidelberg, Germany using
Manders Overlap Coefficient (MOC) [43]. Only neutro-
phils with MOC>0.6 were considered as cells with sig-
nificant co-localization. At least 50 pre-apoptotic
neutrophils from different fields were counted in each
sample.
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MAPK inhibitors included: U0126 (10μM) for MEK1/2
blocking (Signal Transduction, Beverly, MA, USA) and
SB202190 (30μM) for p38MAPK blocking (Calbiocem,
EMD Chemicals, Inc., NJ, USA) [25,44].
Statistical analysis
Data are expressed as mean ± SD. A paired two-tailed
t test was used for single comparison of parametric data.
Values of p<0.05 were considered significant. A paired
two-tailed t test with Bonferroni correction was used to
compare the effects of IH and SH vs. normoxia. There-
fore, for multiple comparisons only values of p<0.017
were considered significant. The NCSS 2004 statistical
package, Kaysville, Utah, USA was used.
Results
IH attenuates Bax translocation to the mitochondria and
its levels
To determine the effects of IH on neutrophil survival,
apoptosis was quantified morphologically by light mi-
croscopy. The percentage of apoptotic neutrophils, as
determined by a single nucleus with dense chromatin
condensation, or nuclear fragments not connected by
strands, was 25.0±6.3% in normoxia. Exposing neutro-
phils to 6 IH cycles or to 6 hrs of SH significantly
decreased the percentage of apoptotic neutrophils (14.5
±6.5%, p=0.0002 IH vs. normoxia; 19.5±5.6%, p=0.016
SH vs. normoxia). These baseline values confirmed our
earlier findings that IH in-vitro increased neutrophil sur-
vival [5,9].
Under confocal microscopy apoptotic neutrophils were
identified by the typical morphology of dense nuclei.
The apoptotic neutrophils were also characterized by a
very high Bax expression (green fluorescence, from
120,000 to 140,000 units), and its fusion with mitochon-
dria (MOC>0.6; yellow-orange dots), as depicted in
Figure 1A. Such apoptotic neutrophils, which are more
prevalent in normoxia, were not investigated in further
experiments, since we focused on earlier mechanisms
that trigger the apoptotic program before visible signs of
apoptosis can be detected. Therefore Bax expression and
its translocation to the mitochondria under the three
oxygen conditions were examined only in pre-apoptotic
neutrophils, characterized by normal nuclear morph-
ology (Figure 1B, C).
Neutrophils of healthy subjects were exposed to IH
and compared by quantitative immunofluorescence to
those exposed to SH and normoxia. In normoxia, pre-
apoptotic neutrophils demonstrated intensive fusion of
Bax with mitochondria, with a shift in fluorescence to
yellow-orange (MOC>0.6), as depicted in Figure 1B. In
contrast, in IH and SH treated neutrophils Bax and
mitochondria were located separately with diffuse Baxdistribution (green fluorescence) and the mitochondria
remained dotted (red fluorescence) in the cytoplasm
(Figure 1C). MOC in IH and SH treated neutrophils was
lower than <0.4, indicating that less than 40% of both
components overlapped. Figure 1D summarizes the
translocation of Bax and its co-localizion with mitochon-
dria for 10 separate experiments. In normoxia, Bax
translocation/co-localization (MOC>0.6) was noted in
53.7±12.9% of the neutrophils. In contrast, after treat-
ment with IH or SH, the percentage of neutrophils with
Bax translocating to the mitochondria was significantly
decreased as compared to normoxia. However, it did not
differ significantly between IH and SH treatments. Bax
expression under the three oxygen conditions is sum-
marized in Figure 1E. Since the average fluorescence in-
tensity of Bax expression per cell varied depending on
the blood donor investigated, Bax expression in nor-
moxia in each subject was considered as 100%, and the
changes induced by IH or SH were plotted as a relative
percentage of this value. The cumulative data
(Figure 1E) show that Bax expression was significantly
down-regulated in neutrophils treated by either IH (by
41%) or SH (by 27%), compared to normoxia. Figure
1F-H depicts representative confocal microscope photo-
micrographs of Bax expression in normoxia, IH, and SH.
After 6 hrs of normoxia the intensity of Bax expression
in pre-apoptotic neutrophils was slightly and non-
significantly increased by 12% as compared to Time 0.
The decrease in Bax expression in the hypoxic condi-
tions was also confirmed by protein levels as determined
by western blot analysis. The following relative values
for Bax expression over β-actin were obtained: nor-
moxia, 1.82±0.7 units; IH, 0.96±0.2 units (p=0.03 vs.
normoxia) and SH, 0.97±0.5 units (p=0.04 vs. normoxia).
A representative immunoblot of Bax protein levels over
β-actin from 6 independent experiments is depicted in
Figure 2A.
IH up-regulates the levels of Mcl-1 protein
Similar to Bax, total Mcl-1 expression was also assessed
at the protein level by western blotting as illustrated in
Figure 2A. The average densitometric analysis from 6 in-
dependent experiments is presented in Figure 2B. In
neutrophils exposed to IH or to SH, Mcl-1 protein fold-
increase over β-actin was significantly higher by about
2-fold compared to normoxia. Also Mcl-1 up-regulation
was observed by confocal microscopy, as illustrated in
Figure 2C. Similar to Bax analysis, the intensity of Mcl-1
expression in normoxia for each subject was considered
as 100% and the changes induced by IH or SH were
plotted as a relative percentage of this value. The specifi-
city of Mcl-1 was confirmed using five-fold excess of the
Mcl-1 blocking peptide, which abolished Mcl-1 fluores-
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Figure 1 Bax expression and co-localization with mitochondria in neutrophils exposed to various oxygen conditions. Bax expression and
co-localization with mitochondria were analyzed by confocal laser scanning microscopy as described in methods. The cytoplasmic distribution of
Bax (green fluorescence) and mitochondria (red fluorescence) was studied by double immunofluorescence labeling. (A) A representative
photomicrograph of an apoptotic neutrophil with a very high Bax expression (140,000 arbitrary units) and intensive fusion of Bax with
mitochondria (yellow), Manders Overlap Coefficient (MOC)>0.6. (B) A pre-apoptotic neutrophil with intensive Bax expression (17,000 arbitrary
units). Bax is translocated and co-localized with mitochondria (yellow and orange), MOC>0.6 representing neutrophils predominantly seen at
normoxia (Nox). (C) A pre-apoptotic neutrophil with low Bax expression (9,500 arbitrary units). Bax (green) and mitochondria (red) are located
separately (MOC<0.6), representing neutrophils predominantly seen in intermittent hypoxia (IH) and sustained hypoxia (SH). (D). The percentage
of
pre-apoptotic neutrophils with fusion of Bax and mitochondria (MOC>0.6) in Nox, IH and SH. Values represent the means ± standard deviations
(n=10). P values represent significance of IH or SH vs. Nox. (E) Relative percentage of Bax expression, assessed by confocal laser scanning
microscopy (n=10). The average fluorescence intensity unit per cell, detected by immunofluorescent quantitation at normoxia was considered as
baseline (100%), and the effects of hypoxia were calculated as relative decrease of Bax expression. P values represent significance of IH or
SH vs. Nox. (F-H) Representative images of Bax expression (green) out of ten experiments in Nox (F), IH (G), and SH (H).








































































Figure 2 Mcl-1 expression in neutrophils exposed to various oxygen conditions. (A) A representative western blot depicting Bax and Mcl-1
expression in normoxia (Nox), intermittent hypoxia (IH) and sustained hypoxia (SH) in one out of six experiments performed. (B) The normalized
values of Mcl-1, obtained by densitometric analysis of western blots are presented as arbitrary units, and depicted as fold induction over β-actin
in Nox, IH and SH. (C) Mcl-1 expression was assessed by confocal laser scanning microscopy (n=8). The average fluorescence intensity unit per
cell, detected by immunofluorescence quantitation at normoxia was considered as baseline (100%), and the effects of IH and SH were calculated
as relative Mcl-1increase. P values represent significance of IH or SH vs. Nox.
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and SH are presented in Figure 3A-C. After 6 hrs of nor-
moxia the intensity of Mcl-1 expression in pre-apoptotic
neutrophils was decreased by about 20% compared to
Time 0.Effects of ERK and p38MAPK inhibition on
Mcl-1 expression
MAPKs, including ERK1/2 and p38MAPK control neutro-
phil survival under certain conditions [27,28,36,44,45]. Spe-
cific p38MAPK and ERK1/2 inhibitors were used to
determine whether Mcl-1 expression was dependent on the
activation of MAPK signaling pathways under IH. Neutro-
phils were incubated in normoxia, SH or IH (as described
in methods) with or without 10 μM U0126 (a specific in-
hibitor of MEK1/2, blocks ERK1/2 activation) or 30 μM
SB202190 (a competitive p38MAPK inhibitor). Mcl-1 dis-
tribution was determined in pre-apoptotic neutrophils by
confocal laser scanning microscopy. Representative images
(from 1 out of 4 experiments performed) of Mcl-1 expres-
sion in the three oxygen conditions without or with the
inhibitors are presented in Figure 3A-I. Figures 3-K depict
the average values of Mcl-1 expression for ERK1/2 inhibitor
and p38MAPK inhibitor by relative percent when normoxia
without the inhibitor was considered as 100%. Blocking
ERK/MEK activity slightly increased (p=0.16) Mcl-1
expression in normoxia but significantly decreased the
IH-mediated Mcl-1 up-regulation by 40%. In contrast, in
SH, Mcl-1 expression was not affected by the ERK/MEK
inhibitor (Figure 3D-F, J). Inhibiting p38MAPK also slightly
increased (p=0.1) Mcl-1 expression in normoxia, but the
hypoxia-induced enhanced Mcl-1 expression, was signifi-
cantly attenuated in both IH (by 30%) and SH (34%) condi-
tions (Figure 3G-I, K).ERK and p38MAPK activation in response to hypoxia
To directly asses ERK1/2 and p38MAPK activation by
IH, their phosphorylation was determined by western
blotting. As depicted in Figure 4A, only IH but not SH
significantly triggered the phosphorylation of ERK1/2.
This pattern of ERK1/2 activation was consistently seen
in each separate experiment performed with neutrophils
isolated from 6 different donors. For comparison with
ERK1/2, we also confirmed our earlier findings showing
that p38MAPK phosphorylation was induced in re-
sponse to both IH and SH [9]. Figure 4B is a representa-
tive immunoblot depicting ERK1/2 and p38MAPK
phosphorylation. Non-phosphorylated controls of ERK1/
2 and p38MAPK did not differ between the treatments.
Bax expression and co-localization in neutrophils of
OSA patients
Bax expression and translocation to the mitochondria
was also assessed in neutrophils of OSA patients. Neu-
trophils cultured for 6 hrs in normoxia or 6 cycles of IH
were compared to controls. Three out of seven studied
patients were obese having a BMI>30. Three out of ten
healthy controls were investigated concurrently with the
OSA patients. All underwent full-night polysomnogra-
phy after which blood samples were taken. Individual
demographic, blood chemistry and sleep data for OSA
patients and the controls are presented in Table 1.
The pre-apoptotic neutrophils of these control sub-
jects expressed Bax translocation to the mitochondria
under normoxia as described earlier for healthy controls
(Figure 5A), and treatment with IH inhibited Bax/mito-
chondria co-localization (Figure 5B). In contrast, in
patients with OSA there was little, if any, Bax transloca-
tion and co-localization to the mitochondria in nor-




















































































 μm μm μm
 μm  μm  μm
Figure 3 Effects of ERK and p38MAPK inhibition on Mcl-1 expression in various oxygen conditions. Neutrophils were incubated for 6 hrs
at normoxia (Nox), sustained hypoxia (SH), or 6 cycles of intermittent hypoxia (IH) without or with 10 μM U0126 (a specific inhibitor of MEK1/2,
which blocks ERK1/2 activation), and 30 μM SB202190 (a competitive inhibitor of the p38 kinase). Mcl-1 expression was assessed by confocal laser
scanning microscopy. (A-I) Representative photomicrographs of Mcl-1 expression (green) from 1 out of 4 experiments performed. (A) Neutrophils
incubated in Nox, (B) IH and (C) SH. (D) Neutrophils incubated in Nox with MEK1/2 inhibitor, (E) in IH with MEK1/2 inhibitor, and (F) in SH with
MEK1/2 inhibitor. (G) Neutrophils incubated in Nox with p38MAPK inhibitor (H) in IH with p38MAPK inhibitor, and (I) in SH with p38MAPK
inhibitor. (J) The average values of Mcl-1 expression for ERK1/2 inhibitor and (K) for p38MAPK inhibitor by relative percent. The intensity of
Mcl-1 expression at normoxia without inhibitors was considered as 100%, and the changes induced by the IH and SH with or without the
inhibitors were plotted as a relative percentage of this value. P values represent significance of untreated vs. inhibitor treated neutrophils in
each oxygen condition.
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low CRP levels (Figure 5C, D) as well as in obese
patients with high CRP levels (Figure 5E, F).
As stated above, the fluorescence intensity of Bax and
Mcl-1 expression was an individual trait. We therefore
used Bax/Mcl-1 ratio for comparing the redistribution of
pro-/anti-apoptotic proteins between OSA and healthy
controls. The average Bax/Mcl-1 ratio in normoxia was
2-fold higher in healthy controls as compared to OSA
patients and was significantly decreased by about 60%
and 50% after treatment with IH and SH, respectively
(Table 2). In OSA patients, the Bax/Mcl-1 ratio was
already low at normoxia (1.0±0.5) and was furtherdecreased after exposure to IH as depicted in Table 2.
Similar values were obtained for Bax/Mcl-1 ratio in nor-
moxia immediately after harvesting the cells (data not
shown).
Discussion
Neutrophils survival was shown to increase in response
to IH in-vitro as well as in-vivo [5,9], however, the
underlying mechanisms are not entirely understood. In
the present study we investigated the contribution of the
mitochondrial stress-induced pathway in prolonging
neutrophil survival under IH treatment in-vitro and in a


























































Figure 4 ERK1/2 and p38MAPK phosphorylation in neutrophils exposed to various oxygen conditions. (A) The average (± SD) normalized
values of p-ERK1/2 (n=6), obtained by densitometric analysis of western blots, are presented as fold increase over β-actin in arbitrary units in
normoxia (Nox), intermittent hypoxia (IH) and sustained hypoxia (SH). (B) A representative western blot depicts the dual phosphorylated
(Thr202/Tyr204) form of ERK1/2 (p-ERK1/2) and dual phosphorylated (Thr180/Tyr182) form of p38MAPK (p-p38) compared to
non-phosphorylated ERK1/2 and p38MAPK in Nox, IH, and SH.
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was decreased, Bax translocation to the mitochondria
was inhibited and the anti-apoptotic protein Mcl-1 was
up-regulated via activation of ERK1/2 and p38MAPK
dependent signaling pathways. In SH treated neutro-
phils, unlike in IH, Mcl-1 up-regulation was onlyTable 1 Demographic, blood chemistry and sleep apnea mea
experiments
No Age BMI AHI % TO Sat <90% TG (mg/dL) C
1 OSA 62 25.2 22 17.3 203.9
2 OSA 64 27.4 19 2.2 50.5
3 OSA 48 34.2 33 6.8 79.9
4 OSA# 74 35.9 61 50.2 116.7
5 OSA*# 42 27.1 15 21.5 80.6
6 OSA 33 37.6 65 45.1 217.2
7 OSA 37 24.7 35 1.9 82.7
Mean 51.4 30.2 35.7 20.7 118.8
SD 15.4 5.5 20.0 19.9 65.7
1 Cont. 57 23.4 9 0 123.7
2 Cont. 38 25.3 9 0 94.2
3 Cont. 57 25.9 6 0 295.0
Mean 50.7 24.9 8 0 171.0
SD 11 1.3 1.7 108.4
Mean† 32.9 25.6 2.1 0 107.9
SD 9.6 2.9 1.8 60
BMI – body mass index, Kg/m2; AHI – apnea hypopnea index; %TO2<90% - Percent
Cholest.- Cholesterol; * - current smoker; # - irregular low-dose acetyl salicylic acid u
and 3 control subjects (cont.) which underwent full-night polysomnography (Techn
fasting after polysomnography. † Mean ± SD of control subjects in which disorderedependent on p38MAPK but not on ERK1/2 activation.
Moreover, using a quantitative confocal microscopy ana-
lysis we have shown that the hypoxia-induced changes
in Bax/Mcl-1 expression and translocation were noted
in neutrophils before the appearance of apoptotic
morphology. Similarly to the in-vitro findings, in OSAsures for patients and controls participating in the
holest. (mg/dL) HDL (mg/dL) LDL (mg/dL) Glucose (mg/dL)
183 26.8 115.6 87.2
215 81 124.3 88.3
154 60.4 77.5 95.9
118 46.3 48.4 71.3
188 35.7 136.2 102.3
145 28.8 72.8 105.9
161 48.3 96 91.8
166 46.8 95.8 91.8
32.0 19.2 31.5 11.4
193 51.5 116.6 87.1
185 59 107.2 90.7
227 28.3 140.1 89.2
201.7 46.3 121.3 89
22.3 16 16.9 1.8
164.2 39.5 103.1 86.54.4
16.6 7.4 18.1
time asleep with arterial oxygen saturation below 90%; TG - Triglycerides;
sage (micropirin-75); Individual data for obstructive sleep apnea (OSA) patients
ion Sleep Medicine Center, Haifa). Blood samples were withdrawn under
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Figure 5 Bax expression and co-localization with mitochondria in neutrophils of OSA patients and controls. Bax expression and
co-localization with mitochondria was analyzed by confocal laser scanning microscopy in neutrophils of OSA patients and controls in normoxia
(Nox) and intermittent hypoxia (IH). The cytoplasmic distribution of mitochondria (red fluorescence) and Bax (green fluorescence) was determined
by double immunofluorescence labeling as described in methods. (A, B) Representative images of a control subject (age=38 yr, BMI=25.3 Kg/m2,
AHI=6.0 events/hrs, CRP=1.48mg/L, 19% apoptotic neutrophils were detected by Giemsa staining). (A) After 6 hrs of normoxia (Nox) Bax is
translocated to and colocalized with mitochondria (yellow and orange). Manders Overlap Coefficient (MOC) >0.6 in neutrophils, (B) IH in-vitro
inhibited Bax translocation to the mitochondria. (C) Representative images of a non-obese OSA patient (age=37 yr, BMI=24.7 Kg/m2, AHI=35.0
events/hrs, CRP=1.99 mg/L, 8% apoptotic neutrophils were detected by Giemsa staining) in normoxia and (D) in IH in-vitro. (E) Representative
images of an obese OSA patient (age=48 yr, BMI=34.2 Kg/m2, AHI=33.0 events/hrs, CRP=8.09 mg/L, 9% apoptotic neutrophils were detected by
Giemsa staining) in normoxia and in (F) IH in-vitro. In obese and non-obese OSA patients Bax was not translocated to the mitochondria; Bax
(green) and mitochondria (red) were located separately in normoxia (C, E) and in IH (D, F).










Controls (n=5) 1.97 ± 0.7 0.8 ± 0.5 1.05± 0.6 0.002† 0.04
Controls* (n=3) 2.0 ± 0.4 1.14 ± 0.4 ND 0.09
Controls pooled
(n=8)
1.99 ± 0.3 0.97 ± 0.2 ND 0.001
OSA (n=7) 1.0 ± 0.5‡ 0.63 ± 0.3 ND 0.09
Normoxia (Nox), intermittent hypoxia (IH), sustained hypoxia (SH).
* - Healthy controls were investigated in parallel with OSA patients in the
Sleep Lab.
ND – not determined. Values represent means ± SD. P1 - statistical
significance, IH vs. Normoxia (Nox); P2 - statistical significance, SH vs. Nox.
†Once Bonferroni correction was added to compare the effects of IH and SH
vs. Nox (for multiple comparisons, values of p<0.017 were considered
significant), only the effects of IH remained significant.
‡−Differences between OSA patients and controls under normoxic conditions,
p=0.015. A paired two-tailed t test was used for a single comparison.
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with the mitochondria and Bax/Mcl-1 ratio was signifi-
cantly lower than in healthy controls.
The Bcl-2 family of proteins is one of the key regula-
tors of cell death at the mitochondrial level [17,19,46-49],
and Bax is the best known pro-apoptotic protein. In most
cell types, the expression and activity of anti-apoptotic
Bcl-2 members is higher than pro-apoptotic members.
By contrast, mature neutrophils constitutively express
pro-apoptotic proteins and the expression of the anti-
apoptotic Bcl-2 members is very low [11,50]. Thus, the
balance between pro- and anti-apoptotic members deter-
mines the fate of cells [51].
High Bax expression and its fusion with mitochondria
were noted in apoptotic neutrophils by confocal micros-
copy analysis. Bax was also abundantly expressed, to a
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jects. However, its expression and translocation to the
mitochondria were significantly lowered under IH as
well as SH in-vitro. Although the critical molecules
which inhibit Bax translocation to the mitochondria are
as yet unknown, a possible candidate might be Mcl-1,
which was up-regulated by nearly 2-fold under IH and
SH. In freshly isolated neutrophils, Mcl-1 is heterodi-
merized in the cytoplasm with Bax. Diminishing Mcl-1
levels release Bax from the heterocomplex Bax:Mcl-1,
and allow Bax to translocate to the mitochondria where
it can exercise its pro-apoptotic function [13,26,46,52].
Its translocation to the mitochondria leads to the release
of pro-apoptotic factors such as cytochrome c, which
complexes with apoptotic protease-activating factor 1
(Apaf-1) and pro-caspase-9 to form a protein complex
the ‘apoptosome’ which is involved in caspase-3 activa-
tion. The latter is responsible for the visible signs of
apoptosis [16,19,48,51,52]. Accordingly, our findings
demonstrate that changes in Bax/Mcl-1 expression and
translocation to the mitochondria were noted before the
appearance of apoptotic morphology, as expected, but
also before caspase activation, as indicated by flow cyto-
metry and confocal microscopy using FAN-FLICA Poly
Caspase Kit (binds the activated caspases-1, -3, -4, -5, -6,
-7, -8, -9) (Dyugovskaya L, Berger S, unpublished
observation).
Mcl-1 has a short half-life (~3 hrs), and spontaneous
apoptosis is accompanied by Mcl-1 degradation [31].
However, its expression may be increased depending on
the stimuli exerted [15]. Mcl-1 expression was increased
in IH and SH in-vitro treated neutrophils compared to
normoxia. It is likely that both IH and SH may induce
Mcl-1 stabilization by preventing its degradation, and/or
possibly by up-regulating its production. Besides in IH
and SH demonstrated in this study, increased Mcl-1
levels have been previously implicated in neutrophil sur-
vival induced by LPS, cytokines such as GM-CSF, IL-1,
TNF-α, IL-15 [24-27,29], leukotriene B4 [28], Toll-like-
receptor agonist [53] and SH for at least 8 hrs at less
than 2% oxygen [31], as obtained in this study for 6 hrs
of SH.
Mcl-1 expression in neutrophils is regulated by a di-
verse array of signal transduction pathways which de-
pend on the stimuli exerted [25,44]. Here, we
demonstrate for the first time that only under IH the
up-regulation of Mcl-1 coincided with p-ERK1/2 activa-
tion, and by inhibiting ERK1/2, the expression of Mcl-1
was inhibited. In contrast, p38MAPK was up-regulated
by both IH as well as by SH as previously shown [9],
and its inhibition affected Mcl-1 expression under both
hypoxic conditions. Also, like in our SH experimental
conditions, similar findings were reported for neutro-
phils exposed to 12 hrs of SH. Inhibition of p38MAPKled to a significant decrease in Mcl-1 expression,
whereas inhibiting ERK1/2 led only to a slight, but not
significant decrease in Mcl-1 levels [30].
The selective ERK1/2 phosphorylation in human neu-
trophils by IH suggests that Mcl-1 activity might be
regulated by different signal transduction pathways in
various hypoxic conditions, such as in IH and SH
demonstrated here. We should note however, that other
pathways not investigated in this study, in addition to
p38MAPK and ERK1/2 could be involved in the up-
regulation of Mcl-1 under IH. For instance, the NF-κB-
dependent up-regulation of IL-8 levels described earlier
for IH [9] may control the expression of survival genes
of Bcl-2 family members [54] by increasing anti-
apoptotic and decreasing pro-apoptotic proteins levels in
neutrophils [55].
Finally we showed for the first time that in OSA
patients Bax translocation to the mitochondria was min-
imal in neutrophils maintained at normoxic conditions,
and it was further reduced in response to IH in-vitro in
all patients investigated regardless of weight differences.
Moreover, the normoxic values obtained for OSA were
similar to those of control neutrophils exposed to IH
in-vitro, illustrating the similarities between in-vitro and
in-vivo IH. Additionally, the ratio Bax/Mcl-1 was signifi-
cantly lower in OSA patients at normoxia as compared
to control subjects clearly demonstrating that pro-
apoptotic Bax was low whereas the anti-apoptotic Mcl-1
protein was high. Collectively, these finding suggest that
the IH-dependent prolonged neutrophil survival in OSA
is largely affected by the mitochondrial stress-induced
pathway.
Elucidating potential mechanisms which might sup-
press neutrophil apoptosis by IH in-vivo, is of a great
importance to OSA and sleep disordered breathing
(SDB). OSA is a prevalent syndrome associated with car-
diovascular morbidity and mortality [56]. It affects at
least 4% and 2% of men and women in the adult popula-
tion. However, the prevalence of SDB (IH without the
characteristic excessive daytime sleepiness) is estimated
to be as high as 24% and 9% in men and women. This
value may rise to 60-90% in obese individuals [57].
Moreover, SDB is also highly prevalent in more than
60% of patients with acute myocardial infarction and in
more than 50% (44-93%) of patients with stroke [56].
Furthermore, OSA and SDB are also associated with
increased vascular inflammation, endothelial dysfunction
and atherosclerosis [56,58].
Study limitations
The limitations of our study regarding the patients with
OSA should be acknowledged. First, the IH experienced
by OSA patients was not mimicked in our IH in-vitro
model due to technical constrains. The short intervals as
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reproduce with neutrophils in culture conditions be-
cause they are non-adherent cells. Therefore, the
medium cannot be replaced at short intervals with alter-
nating preconditioned hypoxic or normoxic medium.
Despite that, the findings in OSA patients were similar
to those obtained by IH in-vitro. Yet, it would be inter-
esting to repeat this type of a study in an animal model
of IH, that allows mimicking the time patterns of IH
more closely to OSA patients and in a dose dependent
manner, and to avoid confounding factors and comor-
bidities [59].
Second, the number of OSA patients investigated in
the current study is relatively small and there are signifi-
cant differences in age and BMI between patients and
controls. However, in a previous study [5] meticulously
and rigorously investigating more than 100 patients we
have shown by linear regression analysis that all apnea
measures (AHI, oxygen desaturation index of 3%, min-
imal oxygen desaturation, and % time spent below 90%
saturation) were significantly correlated with decreased
neutrophil apoptosis, clearly attesting to the importance
of OSA severity. Moreover, using multivariate analysis
we could verify that this relationship was independent of
BMI, age, CRP, triglycerides, and adiponectin. Thus, al-
though some of the patients investigated in the present
study were obese and had higher CRP levels than con-
trols, their results with respect to Bax/Mcl-1 ratio and
the lack of Bax translocation to the mitochondria were
identical to the results obtained in non-obese OSA
patients with low CRP levels and like in the IH in-vitro,
and unlike the normoxic controls’ findings. It is note-
worthy that in the previous study [5] we also demon-
strated the contribution of the IH and the AHI severity
measures, regardless of confounding factors, in attenuat-
ing neutrophil apoptosis by investigating OSA patients
with and without treatment with nasal continues positive
airway pressure (nCPAP), which ameliorates the apneas.
Patients on nCPAP treatment were enrolled and were
investigated on two consecutive nights, one with and
one without nCPAP. Patients demographics, BMI, lipid
profile or CRP were unaffected by omitting the treat-
ment, yet all apnea severity measures were increased
and neutrophil apoptosis was decreased as compared to
the treatment night. These earlier data clearly emphasize
the role played by the IH in increasing neutrophils life-
span, therefore allowing to investigate the mechanisms
of neutrophil apoptosis under conditions of IH in-vivo
in patients as well as in-vitro in healthy controls.
Conclusions
This study demonstrates that Bax/Mcl-1 ratio was sig-
nificantly lowered in neutrophils treated by IH in-vitro
and in patients with OSA by up-regulating the anti-apoptotic Mcl-1 and down-regulating the pro-apoptotic
Bax. As a result of the IH, Bax translocation to the mito-
chondria was prevented. Thus, IH converts the pro-
apoptotic phenotype into an anti-apoptotic one by
modulating the Bcl-2 family members Bax and Mcl-1.
This effect of IH is specifically mediated through ERK1/
2 and p38MAPK signaling pathways whereas in SH it is
mediated only through p38MAPK. Hence, identifying
neutrophil survival pathways affected by IH may lead to
new approaches in treating some sleep apnea complica-
tions associated with endothelial dysfunction and athero-
sclerosis. Moreover, these findings may bear relevance to
other conditions and co-morbidities associated with
components of IH such as physical activity, brief ascents
to altitude, myocardial infarction and cancer.
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